FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2226790321> ?p ?o ?g. }

• W2226790321 abstract "Many pharmaceutical solids can exist in different physical forms including polymorphs, solvates, hydrates and co-crystals. Polymorphism is observed in more than half of all crystalline pharmaceutical drugs. A drug substance can have multiple polymorphs, each exhibiting different properties including solubility, bioavailability, stability, efficacy etc. Inter-conversion of different polymorphs of a drug during its isolation, manufacture, transport and storage can have profound effects on the quality and performance of the drug product. Therefore, in order to ensure reproducible bioavailability of the drug during its shelf life under a variety of storage conditions, it is desirable to develop the most thermodynamically stable polymorph of that compound, although this is not an easy task. Hence, developing drugs that do not have an inherent tendency to crystallise is a potentially promising avenue of investigation for the pharmaceutical industry. For this reason, liquid drug forms of established active pharmaceutical ingredients (APIs) have been proposed as a new approach towards alleviating the problems associated with polymorphism of solid drugs. Ionic liquids, compounds comprised entirely of ions and that melt below 100 oC, exhibit a lack of crystallisation at ambient temperature and pressure as a result of decreased lattice energies in the crystalline state. These compounds are known for their ability to be tailored, where ions can be chosen to obtain ionic liquids with particular characteristics (e.g. water soluble vs. water insoluble ionic liquids etc.) It is therefore possible to combine pharmaceutically active ions with Generally Recognised as Safe (GRAS) counter ions to obtain liquid salt forms of known APIs. This is the basis of the research discussed within. The concept of dual pharmaceutically active ionic liquids, whereby two APIs with synergistic activities are combined in order to obtain ionic liquids with dual pharmaceutical activity, is also explored.Predicting whether a particular ion pair will generate a liquid at room temperature is difficult due to the number of possible combinations of anions and cations and the intricacies of their interactions. In this project, a concept known as “anti-crystal engineering” was employed in order to aid in the selection of ions most likely to produce liquids, and this approach was successful in generating a wide range of pharmaceutically active ionic liquids. These new compounds have been fully characterised and their physical properties are reported. As most organic acid/base drugs are only sparingly soluble in water, while many of the corresponding salts of these drugs are water soluble, pharmaceutically active protic ionic liquids have also been developed in order to extend this research strategy to a wider number of drugs, rendering them water soluble in most cases. In order to gain more information about their potential behaviour in delivery systems, these compounds were subjected to a number of experimental techniques, such as infrared analysis and transport property studies, where their chemical and physical properties were determined. As protic ionic liquids do not necessarily consist entirely of ions, but may also contain small amounts of the acid/base species they are derived from, it is also imperative to determine the degree of proton transfer in these compounds. For the protic ionic liquid to be considered a “pure” salt, and not a mixture of the starting materials and the salt, the proton transfer should be at least 99 %. We have established a relationship between the presence of certain functional groups, the extent of proton transfer and the level of association between ions, which will be a useful tool for the future design of the most efficient liquid protic drugs. Finally, model membrane transport studies were performed using the pharmaceutically active protic ionic liquids. These have shown very promising initial results, indicating that these compounds can be designed to have enhanced membrane transport when compared to the original solid form of the drug. These results are an important step towards the application of liquid APIs." @default.
• W2226790321 created "2016-06-24" @default.
• W2226790321 creator A5087557303 @default.
• W2226790321 date "2017-01-31" @default.
• W2226790321 modified "2023-09-27" @default.
• W2226790321 title "Pharmaceutically active ionic liquids" @default.
• W2226790321 doi "https://doi.org/10.4225/03/5890144519588" @default.
• W2226790321 hasPublicationYear "2017" @default.
• W2226790321 type Work @default.
• W2226790321 sameAs 2226790321 @default.
• W2226790321 citedByCount "0" @default.
• W2226790321 crossrefType "dissertation" @default.
• W2226790321 hasAuthorship W2226790321A5087557303 @default.
• W2226790321 hasConcept C104317684 @default.
• W2226790321 hasConcept C118552586 @default.
• W2226790321 hasConcept C127413603 @default.
• W2226790321 hasConcept C135763542 @default.
• W2226790321 hasConcept C145148216 @default.
• W2226790321 hasConcept C149737253 @default.
• W2226790321 hasConcept C154881586 @default.
• W2226790321 hasConcept C155574463 @default.
• W2226790321 hasConcept C15744967 @default.
• W2226790321 hasConcept C161790260 @default.
• W2226790321 hasConcept C178790620 @default.
• W2226790321 hasConcept C181389837 @default.
• W2226790321 hasConcept C185592680 @default.
• W2226790321 hasConcept C192562407 @default.
• W2226790321 hasConcept C203036418 @default.
• W2226790321 hasConcept C2182769 @default.
• W2226790321 hasConcept C2780035454 @default.
• W2226790321 hasConcept C42360764 @default.
• W2226790321 hasConcept C45904493 @default.
• W2226790321 hasConcept C55493867 @default.
• W2226790321 hasConcept C60644358 @default.
• W2226790321 hasConcept C86803240 @default.
• W2226790321 hasConceptScore W2226790321C104317684 @default.
• W2226790321 hasConceptScore W2226790321C118552586 @default.
• W2226790321 hasConceptScore W2226790321C127413603 @default.
• W2226790321 hasConceptScore W2226790321C135763542 @default.
• W2226790321 hasConceptScore W2226790321C145148216 @default.
• W2226790321 hasConceptScore W2226790321C149737253 @default.
• W2226790321 hasConceptScore W2226790321C154881586 @default.
• W2226790321 hasConceptScore W2226790321C155574463 @default.
• W2226790321 hasConceptScore W2226790321C15744967 @default.
• W2226790321 hasConceptScore W2226790321C161790260 @default.
• W2226790321 hasConceptScore W2226790321C178790620 @default.
• W2226790321 hasConceptScore W2226790321C181389837 @default.
• W2226790321 hasConceptScore W2226790321C185592680 @default.
• W2226790321 hasConceptScore W2226790321C192562407 @default.
• W2226790321 hasConceptScore W2226790321C203036418 @default.
• W2226790321 hasConceptScore W2226790321C2182769 @default.
• W2226790321 hasConceptScore W2226790321C2780035454 @default.
• W2226790321 hasConceptScore W2226790321C42360764 @default.
• W2226790321 hasConceptScore W2226790321C45904493 @default.
• W2226790321 hasConceptScore W2226790321C55493867 @default.
• W2226790321 hasConceptScore W2226790321C60644358 @default.
• W2226790321 hasConceptScore W2226790321C86803240 @default.
• W2226790321 hasLocation W22267903211 @default.
• W2226790321 hasOpenAccess W2226790321 @default.
• W2226790321 hasPrimaryLocation W22267903211 @default.
• W2226790321 hasRelatedWork W145528718 @default.
• W2226790321 hasRelatedWork W1624822012 @default.
• W2226790321 hasRelatedWork W1978272050 @default.
• W2226790321 hasRelatedWork W1992849879 @default.
• W2226790321 hasRelatedWork W2023435116 @default.
• W2226790321 hasRelatedWork W2046179634 @default.
• W2226790321 hasRelatedWork W2046571273 @default.
• W2226790321 hasRelatedWork W2048284581 @default.
• W2226790321 hasRelatedWork W2065390155 @default.
• W2226790321 hasRelatedWork W2105552142 @default.
• W2226790321 hasRelatedWork W2165655216 @default.
• W2226790321 hasRelatedWork W2185858535 @default.
• W2226790321 hasRelatedWork W2187309633 @default.
• W2226790321 hasRelatedWork W2188404643 @default.
• W2226790321 hasRelatedWork W2895851747 @default.
• W2226790321 hasRelatedWork W2989654000 @default.
• W2226790321 hasRelatedWork W2995784407 @default.
• W2226790321 hasRelatedWork W3125490798 @default.
• W2226790321 hasRelatedWork W3128667138 @default.
• W2226790321 hasRelatedWork W850224875 @default.
• W2226790321 isParatext "false" @default.
• W2226790321 isRetracted "false" @default.
• W2226790321 magId "2226790321" @default.
• W2226790321 workType "dissertation" @default.